
Diwakar Davar, MD, assistant professor of medicine, Department of Medicine, Hematology/Oncology, University of Pittsburgh, discusses the rationale for the combination of anti-TIM-3 and anti-PD-1 in multiple tumor types.

Your AI-Trained Oncology Knowledge Connection!


Published: January 22nd 2019 | Updated: